#USA #Miami #Immorta Bio #SenoVax #Natural Killer Cells

Immorta Bio's Innovative Approach to Cancer and Viral Infections

Recent advancements at Immorta Bio Inc., a leading longevity-focused biotechnology firm, highlight a novel strategy in combating age-related health issues, specifically cancer and viral infections. Their recent laboratory findings suggest that the removal of aging cells known as senescent cells can significantly boost the numbers and efficacy of natural killer (NK) cells, vital components of the immune system.

The Role of Senescent Cells

As individuals age, they experience a progressive accumulation of senescent cells. These cells are known for their pro-inflammatory effects, which can contribute to various age-related diseases, including cancer. Immorta Bio's research, documented in a soon-to-be-published patent (patent #63/789,097), demonstrates that treatments aimed at reducing these senescent cells lead to an increase in NK cell activity, thereby enhancing the body's ability to fight off tumors and viral pathogens.

The firm's innovative product, SenoVax™, is at the forefront of this research. Previously, studies have illustrated that SenoVax not only reduces senescent cell populations but also enhances the effectiveness of typical cancer treatments, like chemotherapy and checkpoint inhibitors. Moreover, it appears to stimulate the regenerative capabilities of endogenous stem cells in preclinical models, particularly in rats.

Impact on Cancer and Viral Resistance

Natural killer cells are critical to the immune response against tumors and viruses. A notable correlation exists between the infiltration of NK cells into tumors and improved patient survival rates in various cancer types, including breast and lung cancers. The current findings suggest that therapies targeting senescent cells could provide a dual benefit: reducing cancer opportunities while simultaneously enhancing viral resistance.

Dr. Thomas Ichim, President and Chief Scientific Officer at Immorta Bio, emphasizes the link between aging, higher cancer incidence, and increased vulnerability to viral infections. “Our preliminary research implies that by alleviating the burden of senescent cells, we can not only boost NK cells through conventional senolytics but also through our proprietary SenoVax™, thus improving defense against cancer and viral infections,” he states.

Research models showed that not only were NK cells boosted in quantity and efficacy, but they could also be transferred from treated animals to naïve ones, effectively providing a method for tumor eradication in the latter.

A New Methodology in Cancer Treatment

Dr. Boris Reznik, CEO and Chairman of Immorta Bio, regards SenoVax therapy as a breakthrough in harnessing the body's innate potential to combat cancer. Unlike various other treatment methods that may inadvertently allow cancer to strengthen its defenses, SenoVax aims to eliminate the “senescent shield” that cancer utilizes. This approach paves the way for SenoVax to function as both a stand-alone therapy and an adjuvant to existing treatments, potentially opening new doors for patients who currently have limited response options.

Conclusion

As Immorta Bio continues to explore the nexus between aging and disease, their findings on senescent cell removal and the enhancement of NK cells mark an exciting frontier in both cancer immunotherapy and the treatment of viral infections. For more information about their innovative research initiatives, visit Immorta Bio's website. Stay tuned as they embark on this transformative journey in healthcare, promising a future where aging is treated not solely as an inevitable decline but as a challenge we can effectively meet.